Alexion Pharmaceuticals reports researchers will present late-breaking data from a Phase 1/2 dose-escalating study of ALXN1210, the company’s C5 antibody, in patients with paroxysmal nocturnal hemoglobinuria (PNH).

In another late-breaking poster, researchers will present additional results from a Phase 2 trial evaluating ALXN1007 in patients with acute graft-versus-host disease involving the lower gastrointestinal tract (GI-GVHD).

PNH is a debilitating, ultra-rare and life-threatening blood disorder characterized by complement-mediated hemolysis (destruction of red blood cells). Acute GI-GVHD is a severe and life-threatening rare auto-immune disease that can occur as a complication of stem cell transplantation.